Contact Us
Drug Search Results
More Filters [+]

Enasidenib

Alternative Names: enasidenib, ag-221, ag221, idhifa
Latest Update: 2024-12-14
Latest Update Note: Clinical Trial Update

Product Description

Enasidenib, a selective inhibitor of mutant IDH2 enzymes, was safe and well tolerated in patients with IDH2-mutated myeloid malignancies. (Sourced from: https://ashpublications.org/blood/article/130/6/722/36814/Enasidenib-in-mutant-IDH2-relapsed-or-refractory)

Mechanisms of Action: IDH2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Canada | Greece | United States

Approved Indications: Acute Leukemia | Acute Myeloid Leukemia | Leukemia | Myeloid Leukemia

Known Adverse Events: Diarrhea

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Enasidenib

Countries in Clinic: Australia, Austria, Belgium, Brazil, Canada, Czech Republic, Denmark, France, Germany, Italy, Korea, Netherlands, Russia, Spain, Turkey, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 15

Highest Development Phases

Phase 3: Acute Myeloid Leukemia|Myelodysplastic Syndrome

Phase 2: Acute Monocytic Leukemia|Acute Myelomonocytic Leukemia|Allogeneic Stem Cell Transplant|Anemia|Anemia, Refractory, with Excess of Blasts|Blast Crisis|Chronic Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Juvenile Myelomonocytic Leukemia,|Leukopenia|Myelofibrosis|Myeloproliferative Disorders|Preleukemia|Thrombocytopenia

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
HOVON 150 / AMLSG 29-18

P3

Active, not recruiting

Myelodysplastic Syndrome

2033-03-01

NCT06240754

P2

Recruiting

Thrombocytopenia|Anemia|Leukopenia

2026-09-30

2018-001693-25

P2

Active, not recruiting

Myelodysplastic Syndrome

2026-02-14

2019-001416-30

P2

Active, not recruiting

Chronic Myelomonocytic Leukemia|Acute Myeloid Leukemia|Myelodysplastic Syndrome|Allogeneic Stem Cell Transplant|Acute Monocytic Leukemia|Chronic Myeloid Leukemia|Acute Myelomonocytic Leukemia

2025-06-18

Recent News Events

Date

Type

Title

08/15/2024

News Article

 Bicara Therapeutics Expands Board of Directors with Appointments of Mike Powell, Ph.D., and Christopher Bowden, M.D.

05/23/2024

News Article

 Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms

06/05/2023

News Article

 ENSEM Announces the Promotion of Shengfang Jin, PhD to President & Chief Executive Officer

04/12/2023

News Article

 Nicotine Replacement Therapy Market is estimated to be US$ 302.6 billion by 2032 with a CAGR of 16.5% over the forecast period (2022-2032) -By PMI

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions